NCT01106131View on ClinicalTrials.gov

Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin

PHASE3CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

November 30, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

CKD-501 0.5mg

CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.

DRUG

Pioglitazone 15mg

Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.

Trial Locations (1)

Unknown

Kangbuk Samsung Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY